三阴性乳腺癌应用CIK细胞联合化疗治疗观察

Clinical efficacy of cytokine-induced killer cells combined with chemotherapy for patients with triple-negative breast cancer

目的分析比较细胞因子激活杀伤(cytokine-induced killer,CIK)细胞联合化疗治疗三阴性乳腺癌患者免疫功能变化,评估以CIK细胞联合化疗治疗三阴性乳腺癌的有效性和安全性。方法选取2007年1月-2012年1月南阳市中心医院和广西医科大学第一附属医院110例CIK细胞治疗联合化疗的三阴性乳腺癌患者,选取临床特点相近的病例110例作为对照组行单纯化疗,比较两组患者免疫功能、生存质量、生存时间及安全性。结果 CIK细胞联合治疗组患者CD3+、CD8+、NKT细胞治疗后与对照组相比,细胞百分比明显提高,差异有统计学意义(P<0.05);CIK细胞联合治疗组患者生存质量比对照组有不同程度的提高,生存时间有延长,差异有统计学意义。结论 CIK细胞联合化疗治疗三阴性乳腺癌安全、有效,可延长生存时间,改善患者生存质量。

[ Objective ] To analyze and compare the immune functions of cytokine-induced killer cells（ CIK ） biotherapy combined with chemotherapy in treating patients with triple-negative breast cancer. The safety and therapeutic effectiveness of CIK were evaluated. [ Methods ] 110 patients with triple-negative breast cancer admitted to the Nan Yang central hospital and Guangxi Medical University from January 2007 to January 2012 were treated with the regimen of CIK- based immunotherapy combined with chemotherapy. Another 110 patients with TNBC treated with chemotherapy alone during the same period were taken as controls. The immune function, therapeutic effect, quality of life, and side effects were compared between the two groups. The safety and therapeutic effects of CIK therapy were observed. [ Resluts ] In the group of CIK and chemotherapy, the ratios of CD3~, CD8~, and NKT cells were sig-nificantly higher than that of the control group （P〈0.05）. For short-term curative effect, Life quality was more improved in the group of CIK combined with chemotherapy compared with controls. [ Conclusion ] The combination therapy of CIK with chemotherapy in treatingtriple-negative breast cancer patients is safe and effective and can improve the survival time and the quality of life.